science wire

« BACK

Pharmacology



Results 701 - 750 of 1554.


Health - Pharmacology - 27.08.2017
Novartis Phase III CANTOS study demonstrates that targeting inflammation with ACZ885 reduces cardiovascular risk
Study showed a significant 15% reduction of major adverse cardiovascular events (MACE) in people with a prior heart attack and inflammatory atherosclerosis who were treated with 150mg of ACZ885, in addition to standard of care including lipid-lowering therapy   Effect driven by 24% relative reduction in risk of heart attack; a non-significant 10% reduction in risk of cardiovascular death was observed   Sub-group of study participants whose inf

Health - Pharmacology - 27.08.2017
Novartis announces analysis published in The Lancet showing ACZ885 reduced lung cancer mortality by 77% in the CANTOS study with further studies planned
Novartis announces analysis published in The Lancet showing ACZ885 reduced lung cancer mortality by 77% in the CANTOS study with further studies planned Review of blinded, pre-planned oncology safety analyses revealed a 77% reduction in lung cancer mortality and 67% reduction in lung cancer cases in patients treated with 300mg of ACZ885 CANTOS is the first Phase III clinical trial to support a long-established hypothesis from pre-clinical models

Health - Pharmacology - 24.08.2017
Pioneering study to help pensioners improve health and wellbeing in later life
The National Institute for Health Research (NIHR) has awarded £7 million to the Universities of Birmingham, Edinburgh and Warwick to establish a joint research unit focused on developing global surgical research.

Pharmacology - Health - 24.08.2017
Novartis Kisqali (ribociclib) receives EU approval as first-line treatment for HR+/HER2- locally advanced or metastatic breast cancer in combination with any aromatase inhibitor
Novartis Kisqali (ribociclib) receives EU approval as first-line treatment for HR+/HER2- locally advanced or metastatic breast cancer in combination with any aromatase inhibitor Approval is based on

Health - Pharmacology - 23.08.2017
Common obesity and diabetes drug reduces rise in brain pressure
The University of Birmingham has secured £2 million from the National Institute for Health Research (NIHR) to launch a research group aimed at improving healthcare for patients with lung diseases around the world.

Pharmacology - Health - 22.08.2017
Treating arthritis with algae
Researchers at ETH Zurich, Empa and the Norwegian research institute SINTEF are pursuing a new approach to treating arthritis.

Health - Pharmacology - 21.08.2017
Novartis and Medicines for Malaria Venture launch patient trial in Africa for KAF156, a novel compound against multidrug-resistant malaria
Compound has potential to be a game-changer in malaria elimination, rapidly clearing malaria infection, including resistant strains, and blocking parasite transmission   KAF156 is first compound fro

Health - Pharmacology - 17.08.2017
Hemorrhagic Fevers: Countering Inflammation to Prevent Circulatory Failure
Hemorrhagic fevers are severe viral diseases that are often fatal. Researchers from the University of Basel have now identified messenger substances of the immune system, which in infected mice lead to the development of shock. These results, published in the scientific journal Cell Host & Microbe, open up new possibilities for the development of life-saving therapies.

Pharmacology - Health - 14.08.2017
Drug Approval: New Country Comparison Shows Great Savings Potential
The regulatory requirements for the approval of new drugs vary greatly internationally in regards to the resources allocated to the authorities, the evaluation periods for approval and the fees for the pharmaceutical companies. This reports a study of the European Center of Pharmaceutical Medicine at the University of Basel.

Health - Pharmacology - 03.08.2017
Testing the Limits for the Patients' Benefit
Testing the Limits for the Patients’ Benefit
Radiation therapy using protons is a success story at the Paul Scherrer Institute PSI. For several decades now, doctors have been administering a gentle form of radiation treatment to patients with ocular tumours or those located deep inside the body.

Health - Pharmacology - 25.07.2017
Sandoz expands partnership with World Child Cancer, to help children access treatment in four developing countries
Expanded partnership to help "even the odds" of survival for children with cancer in the Philippines, Myanmar, Mexico and Ghana In developed countries, the survival rate for childhood cancer is 80%,

Pharmacology - Health - 21.07.2017
Roche gains positive CHMP opinion for Actemra / RoActemra in giant cell arteritis
Roche gains positive CHMP opinion for Actemra / RoActemra in giant cell arteritis If approved, Actemra/RoActemra would be the first therapy for the treatment of giant cell arteritis (GCA) in Europe GCA can lead to blindness, aortic aneurysm or stroke if left untreated The positive opinion is based on the outcome of the phase III GiACTA study Roche announced today that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positi

Pharmacology - Health - 21.07.2017
Novartis receives positive CHMP opinion for Rydapt (midostaurin) for newly diagnosed FLT3-mutated acute myeloid leukemia (AML) and three types of advanced systemic mastocytosis (SM)
Novartis receives positive CHMP opinion for Rydapt (midostaurin) for newly diagnosed FLT3-mutated acute myeloid leukemia (AML) and three types of advanced systemic mastocytosis (SM) Recommendation ba

Chemistry - Pharmacology - 19.07.2017
A uranium-based compound improves manufacturing of nitrogen products
A uranium-based compound improves manufacturing of nitrogen products
EPFL scientists have developed a uranium-based complex that can allow nitrogen fixation reactions to take place in ambient conditions.

Life Sciences - Pharmacology - 18.07.2017
Low-dose diazepam can increase social competitiveness
Low-dose diazepam can increase social competitiveness
EPFL scientists have discovered how low-dose anxiolytics increase the social competitiveness of high-anxious individuals by boosting the energy output of mitochondria in an area of the mammalian brain that controls motivation and reward. Psychologists speak of anxiety in two forms: ‘state' anxiety, which refers to anxiety arising from a particular situation; and ‘trait' anxiety, which refers to anxiety as part of a person's overall personality.

Pharmacology - Business / Economics - 18.07.2017
Q2 results confirm full year guidance. Strong pipeline results underpin potential of several highly innovative products
Net sales in line with prior year (0% cc , -2% USD), as growth drivers offset Gleevec/Glivec Gx impact: Cosentyx (USD 490 million, +90% cc) continues strong growth in all three indications Entresto (U

Health - Pharmacology - 17.07.2017
Roche’s OCREVUS (ocrelizumab) approved for relapsing and primary progressive multiple sclerosis in Australia
Roche's OCREVUS (ocrelizumab) approved for relapsing and primary progressive multiple sclerosis in Australia Second approval after the US for OCREVUS as the first and only approved treatment for peop

Health - Pharmacology - 14.07.2017
Novartis confirms 5 year data for first and only fully-human IL-17A inhibitor Cosentyx reinforcing sustained efficacy and safety profile in psoriasis
Novartis confirms 5 year data for first and only fully-human IL-17A inhibitor Cosentyx reinforcing sustained efficacy and safety profile in psoriasis 5 year data from long-term Phase III extension study demonstrate sustained efficacy and safety of Cosentyx in patients with moderate-to-severe plaque psoriasis † Data planned to be presented at a key medical congress in the second half of 2017.

Health - Pharmacology - 13.07.2017
Novartis CAR-T cell therapy CTL019 unanimously (10-0) recommended for approval by FDA advisory committee to treat pediatric, young adult r/r B-cell ALL
Novartis CAR-T cell therapy CTL019 unanimously (10-0) recommended for approval by FDA advisory committee to treat pediatric, young adult r/r B-cell ALL Recommendation based on review of CTL019 r/r B

Health - Pharmacology - 11.07.2017
Ending Leprosy Transmission
Ending Leprosy Transmission
Despite substantial reduction in prevalence over the past decades, leprosy remains endemic in over 120 countries. Approximately 200,000 new cases of leprosy still occur every year as diagnosis is difficult and often delayed. In an article published on July 7, 2017 in the Lancet Infectious Diseases, the Swiss Tropical and Public Health Institute (Swiss TPH) and its partners reviewed innovative tools and approaches to help end leprosy transmission.

Pharmacology - Health - 10.07.2017
Positive phase III results for Roche’s emicizumab in haemophilia A published in The New England Journal of Medicine
Positive phase III results for Roche's emicizumab in haemophilia A published in The New England Journal of Medicine HAVEN 1 showed emicizumab reduced bleed rate by 87% compared with on-demand bypassing agents All 12 secondary endpoints in HAVEN 1 were positive, including an intra-patient comparison that showed emicizumab reduced bleed rate by 79% compared to prior prophylactic bypassing agents Data from HAVEN 1 in adults and adolescents and inte

Pharmacology - Life Sciences - 08.07.2017

Pharmacology - Health - 06.07.2017
Novartis receives approval in the EU for Cosentyx label update, includes long term superiority data versus Stelara in psoriasis
Label update includes 52 week data from CLEAR study demonstrating long-term superiority of Cosentyx versus Stelara in psoriasis , † Update also includes use of Cosentyx in moderate-to-severe scalp ps

Health - Pharmacology - 29.06.2017
Novartis receives EU approval for first-line use of Zykadia in ALK-positive advanced non-small cell lung cancer (NSCLC)
In ALK-positive advanced NSCLC patients, Zykadia demonstrated superior median progression-free survival (PFS) compared to SOC chemotherapy with maintenance † Zykadia benefit was also seen in patients

Pharmacology - Health - 28.06.2017
University of Birmingham awards honorary degrees in 2017
One of the largest clinical trials for prostate cancer led by the University of Birmingham has found that adding Abiraterone to hormone therapy at the start of treatment improves survival by 37 per cent. The trial looked at using Abiraterone as an additional treatment in patients with prostate cancer who were about to start long-term hormone therapy.

Pharmacology - Health - 27.06.2017
Sandoz receives approval in Europe for Erelzi (biosimilar etanercept) to treat multiple inflammatory diseases
European Commission approves Sandoz Erelzi to treat immunological diseases such as rheumatoid arthritis, psoriasis, and psoriatic arthritis Approval of Erelzi provides more treatment options for heal

Health - Pharmacology - 27.06.2017
Fewer pills, more flexibility in dosing: Roche’s new Esbriet tablet formulation approved in Europe for mild to moderate idiopathic pulmonary fibrosis (IPF)
Fewer pills, more flexibility in dosing: Roche's new Esbriet tablet formulation approved in Europe for mild to moderate idiopathic pulmonary fibrosis (IPF) New immediate-release tablet formulation of

Pharmacology - Health - 26.06.2017
Roche’s emicizumab showed positive results in phase III studies (HAVEN 1 and HAVEN 2) in haemophilia A with inhibitors
Roche's emicizumab showed positive results in phase III studies (HAVEN 1 and HAVEN 2) in haemophilia A with inhibitors Emicizumab showed substantial and clinically meaningful reduction in bleeds across two pivotal studies Data from HAVEN 1 in adults and adolescents and interim data from HAVEN 2 in children to be presented at the 26th International Society on Thrombosis and Haemostasis (ISTH) Meeting Roche today announced positive data from the p

Pharmacology - Health - 23.06.2017
NEJM publishes full analysis of Rydapt (midostaurin) Phase III RATIFY trial in newly diagnosed FLT3-mutated acute myeloid leukemia (AML)
Significant overall survival benefit observed for FLT3+ AML patients consistent across FLT3 mutation subgroups, including ITD and TKD Detailed data show Rydapt plus standard chemotherapy improved eve

Health - Pharmacology - 23.06.2017
Novartis Kisqali (ribociclib) receives positive CHMP opinion as first-line treatment for HR+/HER2- locally advanced or metastatic breast cancer in combination with any aromatase inhibitor
Novartis Kisqali (ribociclib) receives positive CHMP opinion as first-line treatment for HR+/HER2- locally advanced or metastatic breast cancer in combination with any aromatase inhibitor CHMP opinio

Health - Pharmacology - 23.06.2017
Novartis pivotal CTL019 6-month follow-up data show durable remission rates in children, young adults with r/r B-cell ALL
83% of patients achieved complete remission (CR) or CR with incomplete blood count recovery within 3 months of treatment with CTL019; consistent with interim ELIANA data † Data evaluating 63 patients demonstrate relapse-free survival and probability of survival in a majority of patients at six months † Advances in CTL019 and ELIANA result from global CAR-T cell therapy collaboration with the University of Pennsylvania † CTL019 is manufactured us

Health - Pharmacology - 23.06.2017
Novartis data shows half of eligible Ph+ CML-CP patients remain in Treatment-free Remission nearly two years after stopping Tasigna
New 96-week data support durability and safety of Treatment-free Remission (TFR) in Ph+ CML-CP patients who stop taking Tasigna [1,2] More than 90% of Ph+ CML-CP patients in ENESTfreedom and ENESTop who stopped Tasigna and were in TFR at 48 weeks remained in TFR at 96 weeks [1,2] 48-week data from same trials recently added to Tasigna SmPC following EC approval; discussions with other regulatory authorities are underway worldwide - Novartis toda

Pharmacology - Health - 23.06.2017
Presentation confirms Venclexta/Venclyxto monotherapy benefit in certain patients with high-risk chronic lymphocytic leukaemia and its potential in other hard-to-treat blood cancers
Presentation confirms Venclexta/Venclyxto monotherapy benefit in certain patients with high-risk chronic lymphocytic leukaemia and its potential in other hard-to-treat blood cancers First in class BCL2-specific oral inhibitor represents a potential new way of treating different blood cancers Efficacy and tolerability confirmed in high-risk patients with relapsed or refractory chronic lymphocytic leukaemia, including those with 17p chromosomal de

Pharmacology - Health - 23.06.2017
Roche presents new data from GALLIUM study reinforcing clinical benefit of Gazyva/Gazyvaro in people with previously untreated follicular lymphoma
Roche presents new data from GALLIUM study reinforcing clinical benefit of Gazyva/Gazyvaro in people with previously untreated follicular lymphoma Longer follow-up showed sustained benefit in progression-free survival of Gazyva/Gazyvaro-based treatment over MabThera/Rituxan-based treatment regardless of chemotherapy regimens People with follicular lymphoma who received Gazyva/Gazyvaro-based treatment reported improvement in health-related qualit

Pharmacology - Health - 23.06.2017
FDA approves Rituxan Hycela (rituximab and hyaluronidase human) for subcutaneous injection in certain blood cancers
FDA approves Rituxan Hycela (rituximab and hyaluronidase human) for subcutaneous injection in certain blood cancers Treatment can be administered in five to seven minutes, compared to 1.5 hour

Pharmacology - Health - 23.06.2017
Novartis combination targeted therapy Tafinlar + Mekinist receives FDA approval for BRAF V600E mutant metastatic non-small cell lung cancer (NSCLC)
Novartis combination targeted therapy Tafinlar + Mekinist receives FDA approval for BRAF V600E mutant metastatic non-small cell lung cancer (NSCLC) Approval provides first targeted treatment in the U

Health - Pharmacology - 22.06.2017
ACZ885 (canakinumab) reduces cardiovascular risk in people who survived a heart attack
Phase III CANTOS study met the primary endpoint, a composite of heart attack, stroke and cardiovascular death, showing that ACZ885 (canakinumab) in combination with standard of care therapy reduces cardiovascular risk in people with a prior heart attack and inflammatory atherosclerosis † Despite current treatments about 40% of heart attack survivors remain at increased risk of† recurrent heart attack, stroke or cardiovascular death because of hi

Pharmacology - Health - 21.06.2017
Novartis achieves important regulatory milestone for AMG 334 (erenumab) in migraine prevention with EMA filing acceptance
AMG 334 (erenumab) is the first anti-CGRP monoclonal antibody developed for migraine prevention to receive EMA regulatory filing acceptance † Filing is supported by a comprehensive clinical program o

Health - Pharmacology - 20.06.2017
Almost half of chronic urticaria patients are not receiving any treatment despite significant disease burden
Novartis real world study shows almost half of chronic urticaria patients are not receiving any treatment despite significant disease burden Urgent need to improve management of chronic urticaria (CU) - a disease that causes itchy, persistent hives and swelling which last more than 6 weeks or recur over months or years - highlighted by study of over 3,700 patients , 42% of CU patients studied are not receiving any treatment for their debilitatin

Pharmacology - Health - 20.06.2017
Novartis RTH258 (brolucizumab) demonstrates robust visual gains in nAMD patients with a majority on a 12-week injection interval
RTH258 achieved the primary efficacy endpoint of non-inferiority to aflibercept in mean change in BCVA from baseline to week 48 , in two head-to-head pivotal Phase III†studies , † 57% and 52% of patients receiving RTH258 6 mg in the respective trials were maintained exclusively on a q12w interval immediately following the loading phase and continuing through week 48 , † In both studies overall ocular and non-ocular adverse event rates for RTH258

Health - Pharmacology - 19.06.2017
Sandoz receives approval in Europe for Rixathon‚? (biosimilar rituximab) to treat blood cancers and immunological diseases
European Commission approves Sandoz Rixathon ‚? to treat blood cancers and immunological diseases. Approval expected to broaden patient access to biologics and enable budget-constrained healthcare systems to reallocate resources to other healthcare priorities.

Health - Pharmacology - 17.06.2017
Novartis International AG: New patient survey highlights need for more action to help severe asthma patients gain control of their disease
Large-scale European patient survey found that 94% of severe allergic asthma patients were unable to fully control their disease ‚? These new data underscore the disconnect between self-perceived control and clinical reality; a potentially limiting factor in patients seeking support to better control their condition ‚? Helping patients recognize the possibilities of living a life with properly controlled asthma is central to a major new global p

Pharmacology - Health - 15.06.2017
Novartis’ Cosentyx shows sustained improvements in signs and symptoms for both AS and PsA in up to 80% of patients at 3 years
Cosentyx ‚? is the first and only IL-17A inhibitor to show sustained improvements in signs and symptoms of ankylosing spondylitis (AS) and psoriatic arthritis (PsA) , ‚? Additional data show rapid and sustained pain relief with Cosentyx as early as Week 3 which is sustained out to 2 years in PsA patients ‚? Patient recruitment underway for the new EXCEED head-to-head clinical trial to show superiority of Cosentyx versus Humira ‚? * in PsA The di

Pharmacology - Health - 15.06.2017
FDA accepts Sandoz regulatory submission for a generic version of Advair Diskus‚?
FDA accepts Sandoz ANDA for substitutable generic version of Advair Diskus ‚? Sandoz believes its combination product will offer asthma and COPD patients same safety and efficacy as reference medicin

Pharmacology - Health - 08.06.2017
Novartis presents data demonstrating efficacy of AMG 334 (erenumab) in migraine prevention at the American Headache Society Annual Meeting
Data from the comprehensive clinical program show AMG 334 (erenumab) is safe and effective at preventing migraine in patients with 4 or more migraine days per month ‚?

Health - Pharmacology - 07.06.2017
Novartis interim results from global, pivotal CTL019 trial show durable complete responses in adults with r/r DLBCL
At interim analysis, three-month overall response rate (ORR) was 45%, with 37% complete response (CR); all patients in CR at three months remained in CR at data cutoff Best ORR was 59%, with 43% achi

Pharmacology - Health - 06.06.2017
Novartis drug Tasigna receives EU approval for inclusion of Treatment-free Remission (TFR) data in product label
Tasigna is the first and only tyrosine kinase inhibitor (TKI) to include information on stopping therapy in Ph+ CML-CP patients in the EU product information Approval based on Novartis trials evaluating TFR with Tasigna in Ph+ CML-CP patients in both the first-line setting and after switching from Glivec ‚?

Pharmacology - Health - 05.06.2017
Phase III study showed Roche‚? s Alecensa (alectinib) reduced the risk of disease progression or death by more than half versus crizotinib as first-line treatment in a specific type of lung cancer
Phase III study showed Roche‚??s Alecensa (alectinib) reduced the risk of disease progression or death by more than half versus crizotinib as first-line treatment in a specific type of lung cancer Second positive phase III head-to-head study to show Alecensa was superior to crizotinib in people with ALK-positive lung cancer Alecensa lowered the risk of tumour spread or growth in the brain or central nervous system Data will be simultaneously pub

Health - Pharmacology - 05.06.2017
Novartis announces ground-breaking collaboration with IBM Watson Health on outcomes-based care in advanced breast cancer
Collaboration will use real-world patient data and cognitive computing with aim of improving outcomes in advanced breast cancer Brings Novartis innovation and breast cancer expertise together with IBM Watson Health proficiency in data analytics and machine learning Collaboration initiating in breast cancer given Novartis heritage and expertise; opportunity to expand to enhance outcomes for patients with other cancers ‚‘‚'‚‘‚'‚‘‚'‚‘‚'‚‘‚'‚‘‚' ‚?

Health - Pharmacology - 05.06.2017
Roche‚? s Perjeta-based regimen reduced the risk of invasive cancer returning compared to Herceptin and chemotherapy in HER2-positive early breast cancer
APHINITY study shows Roche‚??s Perjeta-based regimen reduced the risk of invasive cancer returning compared to Herceptin and chemotherapy in HER2-positive early breast cancer Phase III study confirms

This site uses cookies and analysis tools to improve the usability of the site. More information. |